[go: up one dir, main page]

CO2019007830A2 - Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas - Google Patents

Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas

Info

Publication number
CO2019007830A2
CO2019007830A2 CONC2019/0007830A CO2019007830A CO2019007830A2 CO 2019007830 A2 CO2019007830 A2 CO 2019007830A2 CO 2019007830 A CO2019007830 A CO 2019007830A CO 2019007830 A2 CO2019007830 A2 CO 2019007830A2
Authority
CO
Colombia
Prior art keywords
disease
protein aggregation
methods
heteroaryl derivatives
parkinson
Prior art date
Application number
CONC2019/0007830A
Other languages
English (en)
Inventor
Laurent Provins
Adrian Hall
Malcolm Maccoss
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CO2019007830A2 publication Critical patent/CO2019007830A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con ciertos compuestos bis-heteroarilo bicíclicos de Fórmula (I), las composiciones farmacéuticas que los contienen y los métodos para usarlos, incluidos los métodos para prevenir, revertir, desacelerar o inhibir la agregación de proteínas, y los métodos para Tratamiento de enfermedades asociadas con la agregación de proteínas, incluidas enfermedades neurodegenerativas como la enfermedad de Parkinson, la enfermedad de Alzheimer, la enfermedad de cuerpos de Lewy, la enfermedad de Parkinson con demencia, la demencia fronto-temporal, la enfermedad de Huntington, la esclerosis lateral amiotrófica, la atrofia multisistémica y el cáncer, incluido el melanoma.
CONC2019/0007830A 2017-01-26 2019-07-22 Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas CO2019007830A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17153217 2017-01-26
PCT/EP2018/051584 WO2018138088A1 (en) 2017-01-26 2018-01-23 Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation

Publications (1)

Publication Number Publication Date
CO2019007830A2 true CO2019007830A2 (es) 2019-07-31

Family

ID=57906529

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007830A CO2019007830A2 (es) 2017-01-26 2019-07-22 Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas

Country Status (16)

Country Link
US (1) US10889584B2 (es)
EP (1) EP3573986B1 (es)
JP (1) JP7073385B2 (es)
KR (1) KR20190112022A (es)
CN (1) CN110167937B (es)
AU (1) AU2018212438C1 (es)
BR (1) BR112019011924A2 (es)
CA (1) CA3045221A1 (es)
CL (1) CL2019001891A1 (es)
CO (1) CO2019007830A2 (es)
EA (1) EA201991755A1 (es)
ES (1) ES2884145T3 (es)
IL (1) IL267993A (es)
MX (1) MX2019008256A (es)
RU (1) RU2019126167A (es)
WO (1) WO2018138088A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809440T4 (tr) 2014-01-29 2018-07-23 Ucb Biopharma Sprl Protein agregasyonunun inhibitörleri olarak heteroaril amidler.
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190111080A (ko) * 2017-01-26 2019-10-01 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 비스-헤테로아릴 유도체
ES2884145T3 (es) * 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas
EA201991753A1 (ru) 2017-01-26 2020-01-14 Юсб Байофарма Спрл Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
US20230399323A1 (en) * 2020-08-25 2023-12-14 National Institutes for Quantum Science and Technology NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
WO2011084642A1 (en) 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
CN104363903A (zh) 2012-03-28 2015-02-18 神经孔疗法股份有限公司 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物
EP2872143B1 (en) 2012-07-16 2017-12-13 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
TR201809440T4 (tr) * 2014-01-29 2018-07-23 Ucb Biopharma Sprl Protein agregasyonunun inhibitörleri olarak heteroaril amidler.
ES2885049T3 (es) * 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
KR20190111080A (ko) 2017-01-26 2019-10-01 유씨비 바이오파마 에스피알엘 단백질 응집의 조절제로서의 비스-헤테로아릴 유도체
ES2884145T3 (es) * 2017-01-26 2021-12-10 UCB Biopharma SRL Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas

Also Published As

Publication number Publication date
ES2884145T3 (es) 2021-12-10
EP3573986B1 (en) 2021-05-26
JP7073385B2 (ja) 2022-05-23
RU2019126167A (ru) 2021-02-26
KR20190112022A (ko) 2019-10-02
BR112019011924A2 (pt) 2019-10-29
CN110167937B (zh) 2022-03-29
WO2018138088A1 (en) 2018-08-02
AU2018212438B2 (en) 2020-12-17
EA201991755A1 (ru) 2020-01-22
JP2020505369A (ja) 2020-02-20
CL2019001891A1 (es) 2019-11-22
US10889584B2 (en) 2021-01-12
US20190367513A1 (en) 2019-12-05
CN110167937A (zh) 2019-08-23
CA3045221A1 (en) 2018-08-02
MX2019008256A (es) 2019-09-09
AU2018212438A1 (en) 2019-07-25
EP3573986A1 (en) 2019-12-04
AU2018212438C1 (en) 2021-05-06
IL267993A (en) 2019-09-26

Similar Documents

Publication Publication Date Title
CO2019007830A2 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas
CO2019007835A2 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CO2019007833A2 (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
ECSP17045054A (es) Derivados de fumagilol
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
BR112016030599A8 (pt) novos derivados de aminoalquilbenzotiazepina e suas utilizações